Company / SG&A Expense
CNBX Pharmaceuticals Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$271.7K
FY2025
5-year range
$271.7K / $1.3M
FY2021-FY2025
Trend
-47.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 8 years, ranging from $214,610 in FY2016 to $1M in FY2019.
Based on SEC 10-K filings.
$271,691 in FY2025 with a 5-year CAGR of -27.0%.
Improved from $909,980 to $271,691 over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -27.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -27.0%, indicating a declining trend.
- In FY2025, sg&a expense decreased 47.6% year-over-year.
- Peak sg&a expense was recorded in FY2019.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1304.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $271.7K | -47.6% |
| FY2024 | $518.4K | -43.0% |
| FY2023 | $910.0K | +9.8% |
| FY2021 | $828.6K | -36.7% |
| FY2020 | $1.3M | -11.7% |
| FY2019 | $1.5M | +11.8% |
| FY2017 | $1.3M | +517.5% |
| FY2016 | $214.6K | - |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026